UCB SA - BNP Paribas Fortis

Peter Fellner................................................................................................................................... 60,000
Jean-Pierre Kinet (appointed to the Board on 24 April 2008) ...................................................... 45,000
Gerhard Mayr ................................................................................................................................ 65,667
Norman Ornstein (appointed to the Board on 24 April 2008) ...................................................... 44,000
Arnoud de Pret............................................................................................................................... 73,333
Bridget van Rijckevorsel ............................................................................................................... 60,000
Gaëtan van de Werve ..................................................................................................................... 66,667
Previous Directors
Alan Blinken (term ended 24 April 2008) ..................................................................................... 16,667
Georges Jacobs (term ended 24 April 2008) ................................................................................. 30,000
Guy Keutgen (term ended 24 April 2008) .................................................................................... 16,667
Patrick Schwarz-Schütte (term ended 30 April 2009).................................................................... 59,000
Jean-Louis Vanherweghem (term ended 24 April 2008) ............................................................... 15,000
Until 24 April 2008 the annual emoluments of each member of the Board were €39,000 and for the
chairman of the Board €78,000. Additionally, each member of the Board received meeting attendance
fees of €1,000 (€2,000 for the chairman of the Board) per meeting and an additional remuneration of
€5,000 for each member of the Audit Committee and for each member of the Remuneration and
Nomination Committee (€10,000 for the chairman of each such committee). For the financial year
ended 31 December 2008, the aggregate compensation and other benefits paid to members of the Board
was €933,501.
Based on revised benchmarks which included remuneration of Board members of comparable U.S.
companies and remuneration of Board members of European biopharmaceutical companies the General
Meeting of 24 April 2008 approved, as from that date, that the annual emoluments of the Directors are
now to be €60,000, €120,000 for the chairman of the Board, and €90,000 for the vice-chairperson. The
vice chairperson is now entitled to €1,500 per annum as meeting attendance fees.
Based on 2008 achievements, the Board has approved a salary increase of 2 per cent. in 2009 and the
chief executive officer’s new annual base salary for 2009 will be €1,238,303. The chief executive
officer’s total compensation (base salary and bonus and long-term incentives) for 2008 amounts to
€2,739,294 (excluding pension contributions and other benefits), which is 22 per cent. lower than in
2007. This is caused by the decrease in the value of the long-term incentives.
The following table sets forth the remuneration paid to the members of the Executive Committee during
the financial year ended 31 December 2008. Except for the chairman of the Executive Committee,
Roch Doliveux, whose remuneration is disclosed on an individual basis, the remuneration paid to the
remaining members of the Executive Committee is disclosed on an aggregate basis.
A11250830/2.25/23 Oct 2009 101
Retirement
benefits